AstraZeneca CEO links Europe’s Covid surge to rejection of its vaccine
by Linda Geddes Science correspondent from on (#5S857)
Scientists sceptical about Pascal Soriot's suggestion Oxford jab may give longer-lasting protection
Scientists have reacted with scepticism to claims by AstraZeneca's CEO that low uptake of the Oxford/AstraZeneca jab among elderly Europeans could explain the current surge in Covid-19 infections in mainland Europe.
Pascal Soriot told BBC Radio 4's Today programme that differences in T-cell immunity between the vaccines might mean that those who received the Oxford/AstraZeneca jab had longer-lasting immune protection against the virus. T- cells are a class of immune cells that educate antibody-producing B cells about the nature of the viral threat and directly kill infected cells.
Continue reading...